Literature DB >> 27647464

Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) in children with cancer: A single-center experience.

Athanasios Tragiannidis1, Nikolaos Gombakis2, Maria Papageorgiou2, Emmanuel Hatzipantelis2, Theodotis Papageorgiou2, Maria Hatzistilianou2.   

Abstract

Treatment-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (AML) is a devastating early or late complication of treatment for childhood cancer related with a significant morbidity and mortality. We retrospectively studied survivors of childhood cancer. Overall, 287 patients were recorded in the databases and we identified three (1.04%) with t-MDS. The primary cancer diagnoses were Langerhans cell histiocytosis (one patient) and acute lymphoblastic leukemia (ALL; two patients). The mean age of patients was 12.1 years. All patients had received systemic antifungal treatment for invasive pulmonary aspergillosis successfully treated with voriconazole and liposomal amphotericin B before diagnosis of t-MDS. Two patients (66%) remain alive after a median follow-up period of 3.5 years.
© The Author(s) 2016.

Entities:  

Keywords:  Childhood; treatment-related myelodysplastic syndromes

Mesh:

Substances:

Year:  2016        PMID: 27647464      PMCID: PMC5806816          DOI: 10.1177/0394632016670667

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  4 in total

Review 1.  Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.

Authors:  D R Barnard; W G Woods
Journal:  Leuk Lymphoma       Date:  2005-05

2.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy.

Authors:  C M Rubin; D C Arthur; W G Woods; B J Lange; P C Nowell; J D Rowley; J Nachman; B Bostrom; E S Baum; C R Suarez
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

Review 3.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

4.  Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.

Authors:  Dolly G Aguilera; Christos Vaklavas; Apostolia M Tsimberidou; Sijin Wen; L Jeffrey Medeiros; Seth J Corey
Journal:  J Pediatr Hematol Oncol       Date:  2009-11       Impact factor: 1.289

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.